Disclaimer: Compounded tirzepatide and semaglutide are prepared by a licensed 503A compounding pharmacy and have not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.
Tirzepatide versus semaglutide is the question that comes into our program almost every day. Someone is starting intake, or three months in and plateauing, or they just read something about Mounjaro. Our clinical team has worked through this comparison thousands of times, and my pharmaceutical background lets me explain the difference from the commercial and operational side.
Here is how I think about it, and what we consistently see across our patient population.
The Mechanism Difference, From a Pharmacological Standpoint
Both medications are incretin-based therapies. Incretins are gut hormones released after eating that signal the pancreas to release insulin, slow gastric motility, and reduce hunger. The two that matter here are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the hypothalamus and brainstem, driving satiety and reducing caloric intake, and in the gut, where it slows gastric emptying. Chemical modifications that resist breakdown allow once-weekly dosing.
Tirzepatide activates a second receptor pathway semaglutide does not touch: the GIP receptor. In pancreatic beta cells, GIP receptor activation enhances glucose-stimulated insulin secretion. In adipose tissue, GIP receptors influence lipid metabolism and fat storage dynamics. The molecule is a 39-amino-acid peptide engineered to bind both targets, though not equally: pharmacology studies describe it as an "imbalanced" agonist that favors GIP receptor activity. The combination produces a different biological profile, not simply a stronger version of the same signal.
According to a recent review in The Lancet on next-generation incretin-based medications, tirzepatide is currently the only dual GIP and GLP-1 receptor agonist approved for both type 2 diabetes and obesity. Whether the GIP component drives the additional weight loss seen with tirzepatide, or whether other mechanisms contribute, is still an active area of investigation.
For a complete mechanistic breakdown, see How Semaglutide Works at a Cellular Level. For muscle preservation considerations relevant to both, see The Protein and Resistance Training Protocol for GLP-1 Patients.
Brand Names and Dosing
Much of the confusion comes from brand names. Semaglutide is sold as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral tablet for type 2 diabetes. Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and, since December 2024, moderate-to-severe obstructive sleep apnea in adults with obesity. The active ingredient does not change between brand names of the same drug; the labeled indication does, and that affects insurance coverage and prescribing context.
Both medications start low and escalate gradually, because gastrointestinal side effects concentrate in the dose-escalation phase. Semaglutide for weight management starts at 0.25 mg per week and climbs over roughly 17 weeks to a 2.4 mg maintenance dose. Tirzepatide starts at 2.5 mg per week and climbs over roughly 21 weeks to a maximum of 15 mg, with at least four weeks between increases. Most patients do not need the maximum dose to see meaningful results, and many stay at intermediate doses long term.
What We Actually See Across Our Patient Population
I'll be direct about what our clinical team observes: patients on tirzepatide tend to reach their goals more readily than patients on semaglutide, and the difference is noticeable enough that our providers talk about it constantly. That being said, the question of tirzepatide vs semaglutide for weight loss is more nuanced than a simple answer.
The clearest pattern is the plateau transition. Patients who have stalled on semaglutide at a well-tolerated dose frequently restart progress after their provider transitions them to tirzepatide. That is one of the most common adjustments our clinical team manages. Patients with substantially more total weight to lose tend to see a more pronounced difference on tirzepatide. And patients with type 2 diabetes or significant insulin resistance are the population where our providers find the dual mechanism most clinically relevant.
None of that makes semaglutide a weak option. Plenty of patients in our program do very well on it, reach meaningful weight loss, and stay comfortable there. What it means is that when a provider is choosing between the two, the individual clinical picture drives the decision.
Side Effects: Where They Differ
The two medications share most of their adverse event profile, with gastrointestinal effects leading the list. Patients on semaglutide more commonly report nausea and constipation; patients on tirzepatide more commonly report diarrhea, with somewhat less nausea on average. In the head-to-head trial comparing the two, gastrointestinal events serious enough to stop treatment occurred more often with semaglutide.
Both carry the same FDA boxed warning regarding thyroid C-cell tumors based on rodent data. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use either drug. Both can also cause pancreatitis, gallbladder issues, hypoglycemia (particularly alongside insulin or sulfonylureas), and kidney problems related to dehydration from prolonged vomiting or diarrhea. Significant weight loss on either can also come with loss of lean muscle mass, which is why protein intake and resistance training matter.
Cardiovascular Evidence
This is where the evidence base differs most. The SELECT trial showed that semaglutide reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes, and that data supports a separate FDA-approved indication for cardiovascular risk reduction. Tirzepatide's cardiovascular outcome trials are still maturing; early data points in a favorable direction on cardiometabolic risk factors, but the evidence on major cardiovascular events is not yet as complete. For patients whose priority is cardiovascular risk rather than weight alone, that asymmetry is worth discussing with the prescribing provider.
How Our Clinical Team Approaches the Choice
Our providers make the actual prescribing decisions. They weigh the patient's primary goal (weight reduction, glycemic control, cardiovascular risk), prior response to GLP-1 medications, side effect tolerance, contraindications, and cost. What I observe operationally is that cost and consistency matter as much as raw potency. The price difference between the two is real month over month, and a therapy someone can afford to stay on consistently outperforms a more potent option they stop taking. For a patient doing well on semaglutide at a price they can sustain, there is often no reason to change. For a patient who has plateaued or has more aggressive goals, the conversation shifts. Our providers account for all of that individually. Patients who want to explore the tirzepatide option can review our compounded tirzepatide online program details directly.
A Note on the Current Regulatory Environment
The regulatory landscape for compounded GLP-1 medications has changed materially since 2024. The shortage-based pathway that permitted broad "essentially a copy" compounding of both molecules has ended — tirzepatide's shortage was declared resolved in late 2024, semaglutide's in February 2025. The operative framework now is 503A patient-specific compounding, which requires documented clinical justification for each individual prescription. Both compounded tirzepatide and compounded semaglutide are prepared under this framework and have not been reviewed or approved by the FDA as finished drug products. Because they are not FDA-reviewed, their potency and purity are not assured in the way an approved product's are.
FAQ
Q: Is tirzepatide better than semaglutide for weight loss? In our program, patients on tirzepatide tend to reach their goals more readily, particularly those who plateaued on semaglutide or have more weight to lose. Individual response varies, and our clinical team evaluates each patient's situation individually. Neither compounded tirzepatide nor compounded semaglutide has been reviewed by the FDA, and outcomes cannot be assumed to match those of the approved products.
Q: Which one has fewer side effects? Neither is clearly gentler for everyone. Semaglutide more often causes nausea and constipation, tirzepatide more often causes diarrhea. Most side effects show up during dose escalation and ease once the dose is stable.
Q: Can someone switch from semaglutide to tirzepatide if they stop losing weight? Transitioning between the two is something our clinical team handles regularly. Anyone on our program considering a change should raise it with their provider.
Q: Is tirzepatide more expensive? Yes. Tirzepatide costs more at every step of the supply chain. For patients managing tight budgets, semaglutide remains a meaningful and effective option, and many patients in our program do very well on it.
Q: What happens to weight if someone stops GLP-1 therapy? Appetite regulation tends to return toward baseline after stopping, and many patients find weight returns without a maintenance plan. Our clinical team discusses this before anyone starts so the commitment is understood upfront.
If you want to talk through whether this is right for you, our providers are available online. Start at www.precisiontelemed.com.
This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.
About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.
